Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.
Roche said it will launch a tender offer to fully acquire GenMark at a price of $24.05 per share in an all-cash transaction. The price represented a premium of 43% on GenMarkâs closing share price on Feb. 10, before media speculation about a deal, Roche said.